Novel inhibitor targeting triple integrated stress response kinase HRI, PERK, and GCN2 provides new insights into overcoming resistance to proteasome inhibitors in multiple myeloma

被引：0
|
作者：
Inoue, Yasumichi
Hikami, Koki
Ebara, Shunsuke
Sugiyama, Midori
Oda, Robert
Mizutani, Akio
Yoshida, Misaki
Yamakawa, Hiroko
Yagishita, Shigehiro
Hamada, Akinobu
Hayashi, Hidetoshi
Ri, Masaki
Iida, Shinsuke
Morishita, Daisuke
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 06期
关键词：
D O I：
10.1158/1538-7445.AM2024-1233
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1233
引用
收藏
页数：2
相关论文
共 5 条
  • [1] Targeting the Integrated Stress Response Kinase GCN2 to Modulate Retroviral Integration
    Torres, Chloe
    Garling, Asja
    Taouji, Said
    Calmels, Christina
    Andreola, Marie-Line
    Metifiot, Mathieu
    MOLECULES, 2021, 26 (17):
  • [2] TARGETING GCN2 KINASE-DRIVEN STRESS RESPONSE INACTIVATION TO RESTORE TUMOR IMMUNITY IN METASTATIC TRIPLE NEGATIVE BREAST CANCER
    Vankayalapati, Hariprasad
    Medley, Kyle
    Li, Zhaoliang
    Yan, Dongqing
    Bearss, David
    Welm, Alana
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A911 - A911
  • [3] Nrf2-mediated oxidative stress response is altered during acquired resistance to the proteasome inhibitor, oprozomib, in multiple myeloma
    Gaikwad, Snehal M.
    Zingone, Adriana
    Michalowski, Aleksandra
    Najera, Susana
    Quintanilla-Artega, Anaisa
    Gorjifard, Sayeh
    Simmons, John
    Watson, Nick
    Landgren, Ola
    Huang, Jing
    Mock, Beverly
    CANCER RESEARCH, 2018, 78 (13)
  • [4] A novel small molecule activator of the integrated stress response kinase GCN2 shows potent preclinical antitumor activity as monotherapy and in combination with standard of care agents
    Al-Ani, G.
    Groer, Q.
    Eliott, K. M.
    Rudeen, A. J.
    Zwicker, J. D.
    Javed, S.
    Hood, M. M.
    Dhanak, D.
    Flynn, D. L.
    Smith, B. D.
    EUROPEAN JOURNAL OF CANCER, 2024, 211 : S13 - S14
  • [5] Using acquired resistance to explore the mechanism of action of the integrated stress response/GCN2 activator NXP800-A new developmental agent for platinum-resistant ARID1A mutant ovarian cancer
    Powers, Marissa V.
    Hodgson, Rachel
    Sharp, Swee Y.
    Roe, Toby
    Allen, K. Elizabeth
    Campbell, Susan
    te Poele, Robert
    Cheeseman, Matthew
    Jones, Keith
    Clarke, Paul A.
    Workman, Paul
    CANCER RESEARCH, 2024, 84 (06)
1